key: cord-0938309-xl2kmjwy
authors: Faryar, Kiran A.; Henderson, Heather; Wilson, Jason W.; Hansoti, Bhakti; May, Larissa S.; Schechter‐Perkins, Elissa M.; Waxman, Michael J.; Rothman, Richard E.; Haukoos, Jason S.; Lyons, Michael S.
title: COVID‐19 and beyond: Lessons learned from emergency department HIV screening for population‐based screening in healthcare settings
date: 2021-06-22
journal: J Am Coll Emerg Physicians Open
DOI: 10.1002/emp2.12468
sha: e26c9142fb9eecdd932a7e28e1bccba3143097e4
doc_id: 938309
cord_uid: xl2kmjwy

Emergency departments (EDs) have played a major role in the science and practice of HIV population screening. After decades of experience, EDs have demonstrated the capacity to provide testing and linkage to care to large volumes of patients, particularly those who do not otherwise engage the healthcare system. Efforts to expand ED HIV screening in the United States have been accelerated by a collaborative national network of emergency physicians and other stakeholders called EMTIDE (Emergency Medicine Transmissible Infectious Diseases and Epidemics). As the COVID‐19 pandemic evolves, EDs nationwide are being tasked with diagnosing and managing COVID‐19 in a myriad of capacities, adopting varied approaches based in part on know‐how, local disease trends, and the supply chain. The objective of this article is to broadly summarize the lessons learned from decades of ED HIV screening and provide guidance for many analogous issues and challenges in population screening for COVID‐19. Over time, and with the accumulated experience from other epidemics, ED screening should develop into an overarching discipline in which the disease in question may vary, but the efficiency of response is increased by prior knowledge and understanding.

guidance for many analogous issues and challenges in population screening for COVID- 19 . Over time, and with the accumulated experience from other epidemics, ED screening should develop into an overarching discipline in which the disease in question may vary, but the efficiency of response is increased by prior knowledge and understanding.

COVID, emergency departments, HIV, population screening

Emergency departments (EDs) have played a major and ever-increasing role in the science and practice of population screening for HIV. 1, 2 Knowledge gained during the past 2 decades is broad, spanning areas such as patient and physician engagement, patient selection strategies, linkage to care approaches, operational innovations, systems engineering approaches, and health economics. 1, [3] [4] [5] [6] [7] [8] [9] Perhaps most important,

EDs have demonstrated the capacity for providing testing and linkage to care for large numbers of people from all segments of the population, including those without other points of contact with the healthcare system. [10] [11] [12] The ED also provides an opportunity to leverage its unique place within the healthcare system and play a significant role in supporting surveillance for emerging infectious disease outbreaks. For example,

EDs have played an important role in monitoring trends for infectious diseases such as influenza, and most recently, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), commonly known as COVID- 19 . COVID-19 continues to evolve and has emerged as one of the most historical pandemics of the world, with the United States leading the world in terms of total number of cases. EDs nationwide are being tasked with diagnosing and managing COVID-19 in a myriad of capacities adopting varied approaches based in part on know-how, local disease trends, and the supply chain. In the United States, EDs have, and will continue to be, called on to engage more broadly in public health strategies for purposes of surveillance, triage, case detection, and linkage to care to improve both individual patient care as well as the health of the population they serve. weeks after HIV exposure, just before peak viremia. 13 However, an estimated 10%-60% of individuals with early HIV infection will not experience symptoms. 13 If patients do experience symptoms, they may be so mild that the patient does not seek medical attention. Even if the symptoms are severe or lead to a medical encounter, the presentation is typically non-specific and often undiagnosed. 13 

The utility of available assays varies by disease stage. Nucleic acid testing (NAT) identifies HIV genetic material and can detect disease earlier than other methods. 17 HIV NAT is now widely available but remains expensive and does not provide rapid results. Combining multiple patient samples ("pooling") enables NAT to be used for mass screening, 18 but this is contingent on a low disease prevalence and the ability to combine many samples without loss of test sensitivity or increased contamination. Antigen assays have the advantage of detecting most infections that would be found by NAT with more rapid result availability and reduced cost, but because of decreased specificity, requires confirmation with NAT for diagnosis. 19 Antibody assays indicate infection, but are not sensitive in the earliest stages of disease (before antibodies have been formed) and do not indicate current viral load and the corresponding degree to which the person is infectious.

Because HIV does not lead to immunity or halt pathogenesis, population prevalence of the antibody is always a marker of the proportion with ongoing infection and is not a marker of the proportion no longer infectious and no longer susceptible to disease. Although a detailed description of COVID-19 assay technologies is beyond the scope of this article, EDs will need to continue to be at the cutting edge in terms of integration of optimal assay selection for our setting. Issues to be attentive to include the need for educating both administrators and clinicians regarding selection of approaches for mass screening (versus individual testing), potential utility of different assays for different stages of disease, and the need for regular clinician training regarding the decision making associated with specific assays based on the performance characteristics of the assay being used.

Test accuracy was a primary concern in the beginning of the HIV 

Perhaps the most important lesson from the ED HIV screening experience is that there are multiple approaches, and in the absence of a comparative study demonstrating one best approach, variation between centers is acceptable and leads to innovation. In this section, we Short TATs can be achieved in 1 of 2 ways. The first is a 'rapid' bedside assay for which results are quickly available (ie, minutes) and there is no need to transport the specimen to a central laboratory. 4, 24 In general, this approach has not resulted in the largest possible testing volumes because of the time required for parallel program staff or ED staff to process the assay, the logistical challenges to process many assays simultaneously, and the inability in most cases for rapid test kits to detect very early infection using p24 antigen testing. The alternative is to send the sample to a central lab in a rapid way such that usual processes and assays are completed sufficiently quickly.

This functionally approximates (ie, 1-2 hours) that rapid assay TAT (ie, still available before most patients are discharged). 24 This approach has resulted in larger testing volumes because it leverages the usual processes and samples can be batched and processed on automated platforms. 5 

HIV screening approaches include diagnostic testing when there are signs or symptoms of illness, targeted (or risk-based) screening, and non-targeted (commonly referred to as 'routine' or 'universal' despite falling short in practice) screening without consideration of risk. 3, 25 Complicating this classification scheme is the fact that this refers to the intent of the person ordering the test and not patient characteristics.

For example, a person might order a diagnostic test when the patient was also eligible for targeted screening or a person screened under a non-targeted strategy might also have had signs or symptoms of illness as indications for diagnostic testing.

Applicable to both HIV and COVID-19, local disease prevalence, symptomatology of the disease, site-specific testing capacity, and availability of funding influence which screening approach is preferable.

Diagnostic testing has been suggested as a minimum level of specialty engagement, as the pursuit of a diagnosis for a patient's presenting complaint is fairly consistent with the medical mission of emergency medicine. 26 Even if this was fully implemented, it would be insufficient to capture most patients who have either no symptoms or highly nonspecific symptoms. 2, 25 Screening of patients without symptoms requires an embrace of a public health mission and more of a departure from the core specialty mission of emergent stabilization of individual patients. Screening also requires a more systematic, scaled, and streamlined operational focus that considers a process for massive numbers of patients rather than standard medical care for an individual patient. 21, 22 Because population health and mass screening are relatively new to emergency medicine, EDs are already overwhelmed, 27 and healthcare financing is even more complicated for new initiatives than for long-standing initiatives, the issue of screening remains controversial. 28 Once a center has embraced HIV screening, there is the decision about the degree to which the screening will be limited. To some degree, the volume of tests is limited simply because of imperfect implementation fidelity. To date, even with successful large-scale testing of thousands of patients, no center has succeeded in truly universal HIV screening.

It is also possible to limit screening only to those with recognized risk above that of the baseline population (as witnessed in the beginning of the COVID-19 pandemic). This too remains controversial.

Non-targeted HIV screening is recommended by health authorities in most cases. 29 

Although counseling is the most commonly used term in standard discourse, an advance in HIV screening practices has been distinguishing between education (knowledge transfer necessary but not sufficient for behavior change) and counseling (behavioral interventions specifically intended to motivate change). 4 Counseling interventions have been described for HIV, but have rarely been implemented in the ED setting. 30, 31 Counseling is no longer a required adjunct to testing and is resource intensive. The degree to which HIV education or counseling improves or reduces risk behavior is not well characterized.

Education and counseling procedures vary greatly in ED HIV screening. At one extreme, and especially when test results are negative, there may be no education. Undefined (ie, at provider discretion) education, paper handouts, and printed discharge instructions are all minimally resource intensive. More advanced efforts include video presentation 32, 33 or structured in-person education often provided in conjunction with formal counseling. It could be argued that education and counseling for individuals who test negative (whether for HIV or COVID-19) is equally important for disease prevention.

Regardless of modality used or disease, there is the question of who will provide the service, how it will be accomplished, and with what fidelity. In general, there is always the balance between the opportunity to provide education or counseling to a high-risk population not otherwise receiving intervention versus feasibility challenges and expected efficacy of the intervention. The priority currently remains with increasing testing volumes, even if that entails missed opportunities for either HIV or COVID-19 educational or counseling intervention.

The success of HIV linkage to care is highly dependent on obtaining accurate patient contact information during the index visit, identifying secondary contacts, immediate patient-centered contact in the ED to maintain a follow-up relationship, re-engaging with patients during subsequent visits, and re-linkage to care when patients have fallen out of care. 34, 35 Although the notion of patient follow-up is not intuitive in the ED setting, the additional necessity of COVID-19 source control, contact tracing, and result notification makes reliable follow-up information essential. The intensity and reliability of processes to ensure accurate contact information and secure follow-up are highly variable but tend to be more robust when there is dedicated staff to focus on these issues and the patient is found to be positive. With any current or future infectious disease, the degree to which healthcare systems engage in patient follow-up is essential to the screening cascade.

Contact tracing is a standard component of epidemic control and is one of the many reasons why diagnosis has value for public health. 36 Once a person is diagnosed, it becomes possible to interview that person to identify known contacts who may have been the principle that certain thresholds of contact success and behavioral change must be met for contact tracing to be successful, 36 and v) an understanding that partnership with public health is critical.

For both HIV and COVID-19, social stigma and discrimination among affected patients, social contacts, and healthcare workers is real and can be emotionally crippling. 39 

Aggregate data for population and sentinel surveillance EDs also contribute to surveillance systems simply by virtue of aggregating and reporting their clinical testing data. With the advent of testing algorithms capable of detecting acute HIV, this role has now expanded to the detection of both acute and chronic infection, 5 with similar processes pertinent to ED-based COVID-19 detection. In addition to contributing data to existing systems for population surveillance, EDs may have an expanding role in sentinel surveillance. As HIV outbreaks increasingly occur [44] [45] [46] [47] [48] 50 , EDs could play a role in either early identification of those outbreaks or guiding response as they evolve. In that circumstance, extra support or efficiencies are required. We enumerated lessons learned from HIV screening to provide guidance for managing ED screening during COVID-19 peaks. Examples include increased reliance on health department resources such as disease intervention specialists, use of parallel but separate ED staff for result notification and contact tracing (ie, prevention staff, student workers, social work), and decreased investment in communicating negative results (ie, encouraging a "no news is good news" approach).

As seen with HIV, potential options for funding include separately funding program support or incorporating healthcare financing either through additional payment for services rendered or recognition of downstream cost savings from health events prevented.

Differences in mode of transmission and time course of disease influence who is at risk, which in turn alters decisions about whether and how to target screening based on risk. Routine screening for COVID-19 could mirror universal HIV screening. The resource bur-den for routine (or repeated) COVID-19 screening promises to be even greater than HIV because of concerns for reinfection or infection after vaccination. If limiting screening to those with known exposure or symptoms (a risk-based approach), the number of people meeting this criterion remains quite high. Lastly, policy frameworks lead to differences in payment for testing, documentation of risk at the time of testing, and consent requirements. Even in these areas of difference, the need to systematically address such questions is highlighted by the framework provided.

In summary, this synthesis of lessons learned from decades of ED HIV screening (Table 1) should provide guidance for many analogous issues and challenges in population screening for COVID-19. Over time, and with accumulated experience from other epidemics, ED screening should develop into an overarching discipline in which the disease in question may vary, but the efficiency of response is increased by prior knowledge and understanding.

The authors declare no conflicts of interest.

Kiran Ann Faryar, Heather Henderson, Jason W. Wilson, and Michael S.

Lyons conceived the idea and drafted the manuscript. All authors contributed to the design, reviewed the manuscript, and revised it critically for important intellectual content. All authors gave final approval of the version to be published.

The evolving landscape of HIV screening in the emergency department

Routine opt-out rapid HIV screening and detection of HIV infection in emergency department patients

Operational methods of HIV testing in emergency departments: a systematic review

Nomenclature and definitions for emergency department human immunodeficiency virus (HIV) testing: report from the 2007 conference of the National Emergency Department HIV Testing Consortium

Acute HIV infection and implications of fourth-generation HIV screening in emergency departments

Randomized comparison of universal and targeted HIV screening in the emergency department

Public health conditions for successful broad-scale integration of HIV and HCV screening in emergency departments

Novel emergency department registration kiosk for HIV screening is costeffective

Health department collaboration with emergency departments as a model for public health programs among at-risk populations

Trends and characteristics of US emergency department visits

Out of hours care: a profile analysis of patients attending the emergency department and the general practitioner on call

America's health care safety net: intact or unraveling?

Acute and Early HIV Infection. Clinical manifestations and diagnosis

Human immunodeficiency virus transmission at each step of the care continuum in the United States

The detection and management of early HIV infection: a clinical and public health emergency

Insight Start Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection

Nucleic acid testing and molecular characterization of HIV infections

Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population

Impact of nucleic acid testing relative to antigen/antibody combination immunoassay on the detection of acute HIV infection

Evolution of an electronic health record based-human immunodeficiency virus (HIV) screening program in an urban emergency department for diagnosing acute and chronic HIV infection

Team triage intervention, including licensed practical nurse, to increase HIV testing rates in the emergency department: a quality improvement project

The journey toward routinization: triage nursing and the success of an emergency departmentbased routine HIV testing program

An emergency department registration kiosk can increase HIV screening in high risk patients

Rapid HIV screening in the emergency department

Uncovering HIV infection in the emergency department: a broader perspective

American College of Emergency Physicians. HIV Testing and Screening in the Emergency Department

Emergency department overcrowding in the United States: an emerging threat to patient safety and public health

Public health in the emergency department: overcoming barriers to implementation and dissemination

Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings

Preliminary program evaluation of emergency department HIV prevention counseling

Emergency department HIV testing and counseling: an ongoing experience in a low-prevalence area

Video as an effective method to deliver pretest information for rapid human immunodeficiency testing

Comparison of a video to a pictorial brochure in improving HIV/AIDS and HIV testing knowledge and increasing HIV testing motivation and behavioral skills among adult emergency department patients

Linkage-to-care methods and rates in U.S. emergency department-based HIV testing programs: a systematic literature review brief report

Predictors of linkage to care for a nontargeted emergency department hepatitis C screening program

Contact tracing-Where do we go from here?

Covid-19 contact tracing: a briefing

COVID-19 contact tracing and data protection can go together

Stigma during the COVID-19 pandemic

Covid-19 and social stigma: role of scientific community

Perspectives on the ethical concerns and justifications of the 2006 centers for disease control and prevention HIV testing recommendations

Seroprevalence of HCV, HBV and HIV in two inner-city London emergency departments

Seroprevalence study using oral rapid HIV testing in a large urban emergency department

Community outbreak of HIV infection linked to injection drug use of oxymorphone-Indiana

HIV infection linked to injection use of oxymorphone in Indiana

Outbreak of human immunodeficiency virus infection among heterosexual persons who are living homeless and inject drugs

Notes from the field: hIV diagnoses among persons who inject drugs-Northeastern Massachusetts

Health Advisory: HIV Outbreak Among People Who Inject Drugs (PWID)

Health Insurance Portability and Accountability Act

COVID-19 and beyond: Lessons learned from emergency department HIV screening for population-based screening in healthcare settings